As of 2025-11-01, the Fair Value of BioMark Diagnostics Inc (BUX.CN) is -0.08 CAD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 0.34 CAD, the upside of BioMark Diagnostics Inc is -124.07%.
With the market price of 0.34 CAD and our fair value calculation, BioMark Diagnostics Inc (BUX.CN) is not a good investment. Investing in BUX.CN stocks now will result in a potential loss of 124.07%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 5Y Avg | |
| Net income | -1.09 | -1.45 | -1.84 | -1.43 | -1.93 | -1.55 |
| YoY growth | 9.96% | -32.87% | -26.71% | 22.52% | -35.02% | -12.42% |
| Market Cap (mil) | 35.73 |
| P/E | |
| Forward P/E |
| EPS | -0.02 |
| Avg earnings growth rate | -12.42% |
| TTM earnings | -1.72 |